$MNPR Cashflow Statement | Understand Stock

$MNPR

$71.84 +$1.30 (1.84%) Close

$MNPR Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense (non-cash)
Other income from PPP loan forgiveness
Stock-based compensation expense
Issuance of common stock to Alexion Pharmaceuticals, Inc
Net amortization of investment discounts and premiums

Changes in operating assets and liabilities, net
Other current assets
Accounts payable, accrued expenses and other current liabilities
In-process R&D accrued expenses
Operating lease right-of-use assets and liabilities, net
Net cash used in operating activities
Purchase of investments

Cash flows from investing activities:
Purchase of short-term investments
Maturities of short-term investments
Net cash used in investing activities
Cash flows from financing activities:
Cash proceeds from the sales of common stock under a Capital on DemandTM Sales Agreement
Other offering costs - Capital on DemandTM
Cash proceeds from the sales of common stock under a Capital on DemandTM Sales Agreement, net of commissions, fees and expenses
Taxes paid related to net share settlement of vested restricted stock units
Cash proceeds from the issuance of common stock upon exercise of stock options
PPP forgivable bank loan
Net proceeds from issuance of common stock upon public offering, net of offering costs
Net proceeds from issuance of common stock and concurrent private placement of pre-funded warrants upon registered offering, net of offering costs
Net proceeds from issuance of common stock and concurrent issuance of pre-funded warrants upon public offering, net of offering costs
Repurchase of common stock
Net cash provided by financing activities
Effect of exchange rates
Net increase in cash and cash equivalents
Income taxes paid, net of (refunds)
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period

Effect of exchange rate and valuation changes on cash equivalents
Supplemental non-cash flow information:
Lease liability arising out of obtaining right-of-use asset
Accrued financing fees

Comments